More than 451 patents
With a patent portfolio comprising more than 451 patents, 314 of which have been granted, while 137 are in the examination and evaluation phase, we demonstrate that our bet on innovation is the basis of our differentiation.
314 granted patents
137 in examination
and evaluation phase
The success of
Bemiparin®
Our innovation and development policy is reflected in the success of Bemiparin, the first second-generation, low-molecular-weight heparin, which has become the Company’s main product and is currently marketed in more than 55 countries.
BEMIPARIN®
Treatment of established deep vein thrombosis, with or without pulmonary embolism.
Our R&D investment
In 2016, we invested 17.5 million euros in R&D&I, i.e. 6.6% of our operating income (6% more than in the preceding year).
R&D&i projects
ISM
The ISM® platform allows the sustained release of compounds administered by injection and has the advantage of reducing variability, improving stability and minimizing the number of doses necessary, thus improving the degree of patent adherence to the prescribed treatment.
Glycomics
Glycomics is the study and profiling of the sugars that compose a cell, including the glycosaminoglycans (GAG), which, in addition to their role in regulating blood coagulation, are involved in processes like cell growth, immune response and inflammation.
Multilayer technologies for urethral catheters
One of the most important aspects in the use of stents and urethral catheters is the high prevalence of bacteria that, in some cases, may lead to the appearance of clinical symptoms and complications, including severe sepsis and death.
Find out more about the drug-release platform and glycomics.